Description

Background: In 2012 the U.S. Food and Drug Administration (FDA) approved the drug emtricitabine/tenofovir for use as Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP) after proving to be safe and effective at preventing HIV in multiple peer-reviewed studies. Despite the

Background: In 2012 the U.S. Food and Drug Administration (FDA) approved the drug emtricitabine/tenofovir for use as Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP) after proving to be safe and effective at preventing HIV in multiple peer-reviewed studies. Despite the proven safety and value of PrEP treatment, use remains low in practice.

Reuse Permissions
  • Downloads
    pdf (962.8 KB)

    Download count: 0

    Details

    Contributors
    Date Created
    2018-04-18
    Resource Type
  • Text
  • Collaborating institutions
    College of Nursing and Health Innovation

    Machine-readable links